Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

147
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
147
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

111
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
111
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.5K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.5K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

121
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
121
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

91
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
91

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<b>Three new species of Labeninae (Hymenoptera: Ichneumonidae) from Costa Rica</b>.

Zootaxa·2026
Same author

In Situ Deciphering Internal Electric Field-Accelerated Charge Dynamics and Stable Methanol Dehydrogenation with a 2<i>D</i>/1<i>D</i> ZnIn<sub>2</sub>S<sub>4</sub>/CdS Heterojunction.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

Comparison of donor-derived cell-free DNA fractions between combined heart-lung vs isolated heart or lung transplant recipients.

JHLT open·2026
Same author

Gene-by-Sleep Duration Interaction for Glycemic Traits in over 480,000 Individuals.

medRxiv : the preprint server for health sciences·2026
Same author

BmADARa-mediated RNA editing regulates silk gland development and silk protein expression via miR-3315 targeting BmSuc1 in Bombyx mori.

Insect biochemistry and molecular biology·2026
Same author

Synergistic Effects in 2D/2D Cu<sub>2</sub>MoS<sub>4</sub>/ZnIn<sub>2</sub>S<sub>4</sub> Heterojunction Photocatalysts: Mechanistic Insights into Enhanced Hydrogen Production.

Langmuir : the ACS journal of surfaces and colloids·2026

Related Experiment Video

Updated: Dec 9, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.1K

Comparability Considerations and Challenges for Expedited Development Programs for Biological Products.

Sarah J Schrieber1, Wendy S Putnam2, Edwin Chiu Yuen Chow3

  • 1Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD, 20903, USA. sarah.schrieber@fda.hhs.gov.

Drugs in R&D
|September 11, 2020
PubMed
Summary
This summary is machine-generated.

Expedited programs for biological products face challenges with chemistry, manufacturing, and control (CMC) data due to compressed timelines. A workshop highlighted the need for specific guidance on comparability studies during expedited drug development.

More Related Videos

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.4K
Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.5K

Related Experiment Videos

Last Updated: Dec 9, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.1K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.4K
Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.5K

Area of Science:

  • Pharmaceutical Science
  • Drug Development
  • Regulatory Science

Background:

  • Expedited development programs for biological products present unique challenges.
  • Compressed timelines can impact the generation of essential Chemistry, Manufacturing, and Control (CMC) data.
  • Ensuring product quality and comparability is critical for regulatory approval.

Purpose of the Study:

  • To address the lack of specific guidance on comparability studies for expedited biological product development.
  • To facilitate scientific exchange on considerations and challenges in comparability exercises for expedited programs.
  • To highlight discussions from a US FDA workshop on this emerging issue.

Main Methods:

  • Convening a workshop with clinical pharmacologists, product quality chemists, and industry representatives.
  • Facilitating scientific exchange on comparability studies for expedited biological product development.
  • Reviewing existing guidance (ICH Q5E) and identifying gaps for expedited pathways.

Main Results:

  • Identified challenges in providing adequate CMC information within compressed timeframes.
  • Highlighted the potential delays caused by analytical and pharmacokinetic comparability studies.
  • Recognized the need for specific guidance tailored to expedited development.

Conclusions:

  • Expedited development requires careful planning for comparability studies.
  • Further development of specific guidance is needed to support timely submissions for life-saving medicines.
  • Collaboration between regulatory agencies and industry is crucial for addressing these challenges.